Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAP... by Nigel Garrett, Farzana Osman, Sharana Mahomed, Edmund Capparelli, Nonhlanhla Yende Zuma, Derseree Archary, Penny Moore, Natasha Samsunder, Lynn Morris, Salim Abdool Karim, Catherine Hankins, Carolyn Williamson, Bruno Pozzetto, Kevin Carlton, Richard A Koup, Quarraisha Abdool Karim, Leila Mansoor, Tanuja Narayansamy Gengiah, Ishana Harkoo, Precious Radebe, Izukanji T Sikazwe, Disebo Potloane, Nqobile Myeni, Lucio Gama, Sandeep Narpala, Leonid Serebryannyy, Nicole Doria-Rose

Get full text

A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodies by Evan M. Cale, Chen-Hsiang Shen, Adam S. Olia, Nathan A. Radakovich, Reda Rawi, Yongping Yang, David R. Ambrozak, Anthony K. Bennici, Gwo-Yu Chuang, Emma D. Crooks, Jefferson I. Driscoll, Bob C. Lin, Mark K. Louder, Patrick J. Madden, Michael A. Messina, Keiko Osawa, Guillaume B.E. Stewart-Jones, Raffaello Verardi, Zoe Vrakas, Danielle Xie, Baoshan Zhang, James M. Binley, Mark Connors, Richard A. Koup, Theodore C. Pierson, Nicole A. Doria-Rose, Peter D. Kwong, John R. Mascola, Jason Gorman

Get full text

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials by Myra Happe, Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F. Kelley, Sarah Kabbani, Srilatha Edupuganti, Allison Beck, Florence Kaltovich, Tamar Murray, Susanna Tsukerman, Derick Carr, Carl Ashman, Daphne A. Stanley, Aurélie Ploquin, Robert T. Bailer, Richard Schwartz, Fatim Cham, Allan Tindikahwa, Zonghui Hu, Ingelise J. Gordon, Nadine Rouphael, Katherine V. Houser, Emily E. Coates, Barney S. Graham, Richard A. Koup, John R. Mascola, Nancy J. Sullivan, Merlin L. Robb, Julie A. Ake, Kirsten E. Lyke, Mark J. Mulligan, Julie E. Ledgerwood, Hannah Kibuuka, the VRC 208 and RV 422 study team

Get full text

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial by Lindsay N. Carpp, Ollivier Hyrien, Youyi Fong, David Benkeser, Sanne Roels, Daniel J. Stieh, Ilse Van Dromme, Griet A. Van Roey, Avi Kenny, Ying Huang, Marco Carone, Adrian B. McDermott, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Obrimpong Amoa-Awua, Manjula Basappa, Britta Flach, Bob C. Lin, Christopher Moore, Mursal Naisan, Muhammed Naqvi, Sandeep Narpala, Sarah O’Connell, Allen Mueller, Leo Serebryannyy, Mike Castro, Jennifer Wang, Christos J. Petropoulos, Alex Luedtke, Yiwen Lu, Chenchen Yu, Michal Juraska, Nima S. Hejazi, Daniel N. Wolfe, Jerald Sadoff, Glenda E. Gray, Beatriz Grinsztejn, Paul A. Goepfert, Linda-Gail Bekker, Aditya H. Gaur, Valdilea G. Veloso, April K. Randhawa, Michele P. Andrasik, Jenny Hendriks, Carla Truyers, An Vandebosch, Frank Struyf, Hanneke Schuitemaker, Macaya Douoguih, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Richard A. Koup, Ruben O. Donis, Peter B. Gilbert, On behalf of the Immune Assays Team, the Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team, the United States Government (USG)/CoVPN Biostatistics Team

Get full text